Insider · CIK 0001931356
Matthew Angel
Files at TPST (Tempest Therapeutics, Inc.). First filing Mar 25, 2026, latest Jun 23, 2026.
In brief
Matthew Angel files SEC Form 4 as CEO, president, director and 10% owner at TPST (Tempest Therapeutics, Inc.). Since Mar 25, 2026, Matthew Angel has reported 2 open-market buys worth $1.0M and 0 open-market sells worth $0, the latest filed on Jun 23, 2026.
A track record needs three past buys with six months of prices behind them; Matthew Angel has 0, so none is measured yet.
The newest scored trade: bought $500k of TPST on Mar 24, 2026, filed Jun 23, 2026, scored 51 (moderate). In the last 12 months: 2 buys worth $1.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TPST: Tempest Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | TPSTbuy Tempest Therapeutics, Inc. | $500k 231,482 shares | - | - | |
| 51Moderate | TPSTbuy Tempest Therapeutics, Inc. | $500k 231,482 shares | - | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | TPST Tempest Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By Factor Bioscience Inc. | +231,482 | $2.16 | $500k | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | TPST Tempest Therapeutics, Inc. | POpen-market purchase Series A Warrant (right to buy)derivativeindirect: By Factor Bioscience Inc. | +231,482 | - | - | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | TPST Tempest Therapeutics, Inc. | POpen-market purchase Series B Warrant (right to buy)derivativeindirect: By Factor Bioscience Inc. | +231,482 | - | - | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | TPST Tempest Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By Factor Bioscience Inc. | +231,482 | $2.16 | $500k | 231,482 | Mar 25, 2026 |
| Feb 4, 2026 | TPST Tempest Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +269,621 | $0.00 | $0 | 269,621 | Feb 6, 2026 |
Questions about Matthew Angel
Answered from the filings on this page, as of the latest one.
Is Matthew Angel buying or selling?
In the last 12 months Matthew Angel reported 2 open-market buys worth $1.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $500k of TPST on Mar 24, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthew Angel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Angel has 0.
Where does Matthew Angel file Form 4?
Matthew Angel has filed Form 4 at TPST (Tempest Therapeutics, Inc.) as CEO and President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.